Detecting Alzheimer's Risk Early with a Blood Test and Brain Scan

This patent describes a two-step method to predict early Alzheimer's disease by first checking specific protein levels in a blood sample, and then, if certain markers are low, performing a brain scan to confirm amyloid beta buildup.

What it covers

This patent describes a way to detect early signs of Alzheimer's disease in people who don't yet show memory problems and haven't taken certain medications. First, a blood sample is taken to measure the levels of four specific biomarkers: Acetylcholinesterase (AChE), plasma amyloid beta, Lectin galactoside-binding soluble3 binding protein (LGALS3BP), and ACE (Angiotensin I converting enzyme) (Claim 1). If the levels of LGALS3BP, ACE, and AChE are lower than what's typically found in healthy people without brain amyloid, then a special brain scan called a PET test using Pittsburgh compound B (PIB) is performed (Claim 1). This two-step process helps identify individuals who might be accumulating amyloid beta in their brain, a key sign of Alzheimer's, before symptoms appear. For example, if a person with normal memory has low levels of these three blood proteins, the patent suggests they should get a PIB-PET scan to check for amyloid plaques.

What it doesn't cover

• —Does not cover methods for subjects already diagnosed with cognitive impairment or Alzheimer's dementia.
• —Does not cover subjects who are currently being treated with an Acetylcholinesterase (AchE) inhibitor.
• —Does not cover diagnostic methods that rely solely on a PET scan without the initial blood biomarker screening step.
• —Does not cover methods that use a different set of blood biomarkers, or fewer than the four specified (AchE, plasma amyloid beta, LGALS3BP, ACE) in the initial screening.
• —Does not cover methods where the decision to perform a PET test is not based on decreased levels of LGALS3BP, ACE, and AChE.
• —Does not cover methods that use a brain imaging technique other than a PIB-PET test for confirmation.

The clever bit

The clever part is using a specific combination of four blood biomarkers as a preliminary screen. This allows for a more targeted approach, recommending the more expensive and complex PIB-PET brain scan only for individuals who show a particular pattern in their blood, making early detection more efficient.

Why it matters

Early detection of Alzheimer's disease is crucial because it allows for potential interventions before significant brain damage occurs. This patent offers a less invasive initial screening method compared to immediate brain imaging, which can be expensive and involve radiation. Identifying individuals at a preclinical level could enable earlier lifestyle changes or participation in clinical trials for new treatments, potentially slowing disease progression.

Real-world examples

• 1.Research studies on early Alzheimer's detection
• 2.Clinical trials for new Alzheimer's drugs
• 3.Future diagnostic panels for neurodegenerative diseases
• 4.Blood tests for amyloid accumulation risk